Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as education… Read more
Oncology Institute Inc (TOI) - Net Assets
Latest net assets as of September 2025: $-12.27 Million USD
Based on the latest financial reports, Oncology Institute Inc (TOI) has net assets worth $-12.27 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($163.62 Million) and total liabilities ($175.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.27 Million |
| % of Total Assets | -7.5% |
| Annual Growth Rate | -38.91% |
| 5-Year Change | -87.23% |
| 10-Year Change | N/A |
| Growth Volatility | 129.64 |
Oncology Institute Inc - Net Assets Trend (2019–2024)
This chart illustrates how Oncology Institute Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncology Institute Inc (2019–2024)
The table below shows the annual net assets of Oncology Institute Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.59 Million | -93.71% |
| 2023-12-31 | $57.02 Million | -53.70% |
| 2022-12-31 | $123.17 Million | +18.26% |
| 2021-12-31 | $104.16 Million | +270.66% |
| 2020-12-31 | $28.10 Million | -33.45% |
| 2019-12-31 | $42.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncology Institute Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20479797700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.22% |
| Other Components | $214.39 Million | 5973.64% |
| Total Equity | $3.59 Million | 100.00% |
Oncology Institute Inc Competitors by Market Cap
The table below lists competitors of Oncology Institute Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Liaoning Fu-An
SHG:603315
|
$278.47 Million |
|
Hangzhou Weiguang Electronic Co Ltd
SHE:002801
|
$278.49 Million |
|
Tanla Platforms Limited
NSE:TANLA
|
$278.61 Million |
|
Jiangsu Holly Corp
SHG:600128
|
$278.62 Million |
|
Village Farms International Inc
NASDAQ:VFF
|
$278.43 Million |
|
Matrix Service Co
NASDAQ:MTRX
|
$278.38 Million |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
$278.37 Million |
|
Jw Pharmac
KO:001060
|
$278.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncology Institute Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,025,000 to 3,589,000, a change of -53,436,000 (-93.7%).
- Net loss of 64,663,000 reduced equity.
- Other factors increased equity by 11,227,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-64.66 Million | -1801.7% |
| Other Changes | $11.23 Million | +312.82% |
| Total Change | $- | -93.71% |
Book Value vs Market Value Analysis
This analysis compares Oncology Institute Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 75.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.48x to 75.06x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.66 | $3.59 | x |
| 2020-12-31 | $0.48 | $3.59 | x |
| 2021-12-31 | $1.57 | $3.59 | x |
| 2022-12-31 | $1.53 | $3.59 | x |
| 2023-12-31 | $0.77 | $3.59 | x |
| 2024-12-31 | $0.05 | $3.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncology Institute Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1801.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.44%
- • Asset Turnover: 2.28x
- • Equity Multiplier: 48.12x
- Recent ROE (-1801.70%) is below the historical average (-336.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -9.52% | -2.59% | 2.61x | 1.41x | $-8.24 Million |
| 2020 | -50.96% | -7.64% | 2.85x | 2.34x | $-17.13 Million |
| 2021 | -10.49% | -5.38% | 1.00x | 1.95x | $-21.34 Million |
| 2022 | 0.12% | 0.06% | 0.96x | 2.12x | $-12.17 Million |
| 2023 | -145.67% | -25.62% | 1.55x | 3.67x | $-88.77 Million |
| 2024 | -1801.70% | -16.44% | 2.28x | 48.12x | $-65.02 Million |
Industry Comparison
This section compares Oncology Institute Inc's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $250,407,165
- Average return on equity (ROE) among peers: -38.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncology Institute Inc (TOI) | $-12.27 Million | -9.52% | N/A | $278.45 Million |
| Addus HomeCare Corporation (ADUS) | $113.86 Million | 16.82% | 0.44x | $1.75 Billion |
| agilon health Inc (AGL) | $126.73 Million | -319.84% | 9.03x | $166.17 Million |
| Airsculpt Technologies Inc (AIRS) | $123.68 Million | 6.13% | 0.45x | $16.62 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.26 Billion |
| AMN Healthcare Services Inc (AMN) | $347.86 Million | 23.54% | 1.53x | $624.22 Million |
| American Shared Hospital Service (AMS) | $20.85 Million | 8.48% | 1.33x | $7.93 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $112.23 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.08 Billion | 4.65% | 3.71x | $225.22 Million |
| Arem Pacific Corporation (ARPC) | $-45.09K | 0.00% | 0.00x | $246.12K |
| Astrana Health Inc (ASTH) | $8.55 Million | -109.27% | 1.29x | $1.08 Billion |